Loading
LY4050784 / Cisplatin / Advanced Solid Tumor · Phase 1 Trial
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 trial registration for LY4050784, a novel agent targeting SMARCA4-altered tumors, currently recruiting participants with advanced or metastatic solid tumors. No efficacy or safety results are yet reported in this registry record; the study aims to establish the maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity over approximately 4 years.
Phase 1, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor; age from 18 Years. Intervention: LY4050784 (Phase 1a - Dose Escalation); LY4050784 (Phase 1b - Dose Optimization/Part A); LY4050784 (Phase 1b - Dose Expansion/Part B); LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1; LY4050784 (Phase 1b - Dose Expansion/Part C) Coh…. Compared with: Combination cohorts with pembrolizumab, cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel in Phase 1b Part C; no control arm specified in Phase 1a.. n = 340. 33 sites across 6 countries.
This is a Phase 1 trial registration for LY4050784, a novel agent targeting SMARCA4-altered tumors, currently recruiting participants with advanced or metastatic solid tumors. No efficacy or safety results are yet reported in this registry record; the study aims to establish the maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity over approximately 4 years.
This is Phase 1; primary focus is safety and dose-finding, not efficacy.
This trial is in early recruitment and has not yet generated efficacy or safety data. Clinicians should not alter practice based on this registry record; the study will evaluate a novel targeted agent and define appropriate dosing over the coming years.
This is a Phase 1 clinical trial registration with no posted results; it is a first-in-human safety and dose-finding study in early stages of recruitment.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early recruitment and has not yet generated efficacy or safety data. Clinicians should not alter practice based on this registry record; the study will evaluate a novel targeted agent and define appropriate dosing over the coming years.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06561685). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 340 participants (ESTIMATED). Conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor. Interventions: DRUG: LY4050784; DRUG: Pembrolizumab; DRUG: Cisplatin; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Paclitaxel; DRUG: Nab paclitaxel. Primary outcome measures: Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) , Up to Approximately 48 Months or 4 Years; Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784 , Up to Approximately 48 Months or 4 Years; Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR) , Up to Approximately 48 Months or 4 Years; Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784 , Up to Approximately 48 Months or 4 Years; Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents , Up to Approximately 48 Months or 4 Years. Brief summary: The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.